BeOne Medicines Ltd. - Sponsored ADR ONC
360.85
0.88
0.24%
as of 25 Sep
- Market cap
- $37.3B
- P/E
- 61.2×
Follow ONC
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 14.66% | 12.42% | 7.46% | 1.81% |
+8 more TTM periods Free account |
|
| 8.47% | 7.13% | 4.07% | 1.02% | ||
ROIC |
60.22% | 46.03% | 36.03% | 49.21% | |
Return on Tangible Assets |
9.73% | 7.98% | 4.75% | 1.39% | |
Average Days of Receivables |
62.90 | 59.66 | 59.10 | 63.37 | |
Free Cash Flow per Share |
11.92 | 10.05 | 8.45 | 4.76 | |
Free Cash Flow |
1,330.19 | 1,114.61 | 921.74 | 524.60 | |
Capital Expenditures |
(153.87) | (170.22) | (205.84) | (260.80) | |
Piotroski F-Score |
7.00 | 7.00 | 7.00 | 8.00 | |
| Other line items | |||||
Cash ROIC |
13.30% | 12.22% | 11.42% | 9.46% | |
Accounts Receivable Turnover |
6.71 | 6.93 | 6.93 | 6.94 | |
Accounts Payable Turnover |
1.64 | 1.70 | 1.51 | 1.99 | |
Inventory Turnover |
1.10 | 1.14 | 1.21 | 1.43 | |
Average Days of Payables |
252.19 | 230.48 | 261.54 | 203.94 | |
Days of Inventory on Hand |
392.84 | 370.90 | 332.07 | 282.62 | |
Tax Rate |
(0.24) | (0.22) | (0.31) | (0.62) | |
Research and Development Expense of Revenue |
37.41% | 38.42% | 40.16% | 41.68% | |
Selling, General and Administrative Expense of Revenue |
36.43% | 37.94% | 38.96% | 40.84% | |
Share Based Compensation of Revenue |
8.57% | 9.39% | 9.56% | 9.95% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
2.26 | 2.50 | 3.93 | 11.46 | |
Depreciation/Fixed assets |
0.09 | 0.09 | 0.09 | 0.10 | |
Capex/Depreciation |
(0.99) | (1.13) | (1.45) | (1.67) | |
Revenue per Share |
54.93 | 51.72 | 48.99 | 45.12 | |
Operating CF per Share |
13.30 | 11.58 | 10.34 | 7.13 | |
Capex per Share |
(1.38) | (1.53) | (1.89) | (2.37) | |
Capex to Sales |
0.03 | 0.03 | 0.04 | 0.05 | |
Net Profit Margin |
10.70% | 8.94% | 5.37% | 1.38% |
Columns are period end dates